de Boer Daniel Anton purchased $261K of PRQR
de Boer Daniel Anton (Chief Executive Officer) purchased 150,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.74 ($0.26M total) on 2026-07-09.
How this was made
The 30-second read
Why it matters
The only new fact is the disclosed buy size, price, and post-transaction holdings. It provides a sentiment datapoint but no new company fundamentals.
Market read
Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to be a primary catalyst.
What to watch
The filing does not state intent, timing constraints, or whether the CEO’s broader trading pattern is increasing or decreasing.
Background
This is an SEC Form 4 insider transaction disclosure for ProQR Therapeutics N.V. (PRQR), reported as an open-market purchase by the CEO.
Ticker impact
CEO de Boer Daniel Anton filed a Form 4 open-market purchase of 150,000 PRQR shares for about $261,000 on 2026-07-09.
Low likelihood of a sustained price move; any reaction is likely limited and short-lived unless accompanied by other catalysts.
The article is a primary-source insider transaction disclosure with defined size and price, but it does not include new operational, clinical, or financial information.
Market effects
Limited read-across to biotech sentiment; insider buys are common and typically not sector-moving without accompanying fundamentals.
None indicated.
None indicated.
Counterpoint
The purchase may reflect routine liquidity needs or diversification rather than a strong forward-looking view, especially without a 10b5-1 plan.
Key entities
- issuerProQR Therapeutics N.V.
Subject of the Form 4 insider transaction disclosure.
- insiderde Boer Daniel Anton
CEO and director who purchased shares via open-market purchase.